News

At the Conference on Retroviruses and Opportunistic Infection (CROI) in early March, Dr. Deborah Persaud announced that four children had achieved HIV remission. She sat ...

Immediate treatment after an infection theoretically has a better chance of shrinking viral reservoirs. With adults, people rarely know with precision when they became infected, but the timeline is clearer for babies infected in utero. Once treatment has depleted the reservoirs, they should be easier for the immune system to contain. Over time, in theory, it could destroy all HIV-infected cells, or at least all the cells capable of producing virus.

The woman, known as the “New York Patient,” needed a stem cell transplant after doctors diagnosed her with acute leukemia, according to a report published in the ...

PAVE Investigators and Team Members will have several presentations during the pre-conference, main conference, e-posters, and significant presence at the Global Village.

Following a cutting-edge treatment four years ago, the “New York patient” is now off of HIV medication and remains “asymptomatic and healthy,” researchers say.  

In an HIV.gov video conversation on February 16, NIH’s Dr. Carl Dieffenbach discussed some of the pivotal HIV research advances presented this week at the ...

Additional Funding Includes Effort Focused on Pediatric Populations August 17, 2021 The National Institutes of Health has awarded approximately $53 million in annual funding over ...

Emory University received two grants amounting to $25 million and $26.7 million each from the National Institutes of Health (NIH) for research into HIV cures on Aug. 17. The grants, which will be disbursed over the next five years, are part of a larger $53 million per annum award by the NIH to 10 research organizations that are part of the Martin Delaney Collaboratories for HIV Cure Research.

Emory University and the Yerkes National Primate Research Center will share with the Johns Hopkins University School of Medicine in a five-year, $27.6 million award from the National Institutes of Health (NIH) to accelerate the search for a cure for HIV in children and adolescents. The Pediatric Adolescent Virus Elimination (PAVE) Collaboratory is using a multidisciplinary, multicultural and iterative approach to study pediatric HIV. The $5.7 million annual grant is part of the Martin Delaney Collaboratories (MDC) for HIV Cure Research program.